Notably, L18I combined with dasatinib showed increased efficacy in ibrutinib-resistant cells.6 In addition, the PROTAC-MG hybrid DD-03-171, targeting both BTK and the regulatory factors IKFZ1/3, significantly improved survival rate in mouse models of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).317 Recent innovations have introduced photocaged PROTACs for BTK, which enable controlled release and targeted degradation.318 The oral bioavailability of BTK-targeting PROTACs has been enhanced through structural optimizations. Here, BTK is linked to mantle cell lymphoma.